enVVeno Plans June 9 Investor Webcast to Highlight First FDA IDE Approval
NVNO•enVVeno Medical will host a virtual investor event on June 9 at 4:00 PM ET featuring CEO Robert Berman. He will discuss its FDA IDE approval for the first-in-class enVVe System, a non-surgical replacement venous valve in a U.S. pivotal study.
1. Virtual Investor Event Details
enVVeno Medical will host a virtual investor closing bell event on June 9, 2026 at 4:00 PM ET, featuring Chief Executive Officer Robert Berman. The live video webcast will include a presentation and a question and answer session, with a replay available two hours after the event and accessible for 90 days.
2. FDA IDE Approval of enVVe System
The company recently secured the first-ever FDA IDE approval for a U.S. pivotal study of its enVVe System, a bioprosthetic, non-surgical replacement venous valve designed to treat severe deep venous insufficiency. Delivered via transcatheter under light sedation, the enVVe procedure aims to restore one-way valve function without overnight hospitalization.
